Acorai, a Helsingborg, Sweden-based medical device manufacturer, raised $4M in funding.
The round was led by Solardis Health Ventures, with participation from KHP Ventures, Carma Fund and other US investors, including CerraCap Ventures.
The company secured more than $4.5m finance its clinical studies and move towards regulatory approval.
Acorai is developing a non-invasive intracardiac pressure monitoring device to improve heart failure management for more than 64 million patients worldwide. Its monitoring system was designated as a breakthrough device by the US FDA in August 2023 and is built upon the patented SAVE Sensor System, a proprietary, non-invasive hardware and machine learning platform.
The team, led by Filip Peters, Jakob Gelberg, Kasper Bourdette, and Matthew Mace, is planning the completion of their study in 2024, and through active engagement with regulators, Acorai is targeting US market access by 2025.
FinSMEs
22/01/2024